all the information, none of the junk | biotech • healthcare • life sciences

The Seattle Biotech Survival Index: Companies Bounce Back in Mid-2009

(Page 3 of 3)

Cash on hand: $262.9 million
Related Xconomy coverage:
SonoSite Buys CardioDynamics for $12.3M
SonoSite Sales Dip 12 Percent

Targeted Genetics (NASDAQ: TGEN)
Cash on hand: $2.5 million
Related Xconomy coverage:
Targeted Genetics Survives Brush With Death, Sells Gene Therapy IP to Genzyme for $7M
Targeted Genetics Cuts Workforce in Half in Bid to Survive Into August
Stewart Parker Resigns from Targeted Genetics After Gene Therapy Setbacks
Targeted Genetics, Mainstay of Gene Therapy, Faces Likely Shutdown
Targeted Genetics’ Legacy: No Cures, But a Generation of Seattle Biotechies

Trubion Pharmaceuticals (NASDAQ: TRBN)
Cash on hand: $37.4 million
Related Xconomy coverage:
Trubion Gets $20M Upfront in Leukemia Drug Partnership With Facet; Shares Boom
Trubion Pushing Forward Arthritis Trials, Working to Re-Ignite the Spark for Investors
Trubion Cuts One-Fourth of Workforce
Pfizer’s Bid For Wyeth Sends Ripples Through Trubion Pharmaceuticals, Seattle Biotechs

To purchase a much expanded version of this report, in PDF format, click the “Add to Cart” button.
For $95,* you’ll get an assessment of each company’s financial position at the end of June compared to six months earlier, the projected length of time it can survive on its existing cash reserves, and an analysis of the strategic moves it has made to stay afloat in the current environment. Click here to see a sample entry. Add to Cart
*Price is subject to change without notice

ZymoGenetics (NASDAQ: ZGEN)
Cash on hand: $118.2 million
Related Xconomy coverage:
ZymoGenetics Snags $1.1 Billion Partnership With Bristol-Myers For Hepatitis C Drug
ZymoGenetics Plays Hardball, Asks FDA to Pull Competing Drug Off Market Because of Safety
ZymoGenetics Drug Sales Still Slumping After Full Year on Market
ZymoGenetics’ New Boss Sees Parallels to Dark Days at Immunex
ZymoGenetics Clamps Down on Losses, Predicts Climbing Recothrom Sales
ZymoGenetics Cuts One-Third of Workforce To Hold Onto Cash
ZymoGenetics Unloads Drug Candidates to Cut Costs, Spin Off New Company

Single PageCurrently on Page: 1 2 3 previous page

By posting a comment, you agree to our terms and conditions.